Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: a series from lysa centers
C Rossi, J Gilhodes, M Maerevoet… - American journal of …, 2018 - Wiley Online Library
Anti‐PD‐1 therapy provides high response rates in Hodgkin lymphoma (HL) patients who
have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and …
have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and …
[PDF][PDF] Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa …
academia.edu
Anti-PD-1 therapy provides high response rates in Hodgkin lymphoma (HL) patients who
have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and …
have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and …
Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers
C Rossi, J Gilhodes, M Maerevoet, C Herbaux… - American Journal of …, 2018 - hal.science
Anti-PD-1 therapy provides high response rates in Hodgkin lymphoma (HL) patients who
have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and …
have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and …
Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.
C Rossi, J Gilhodes, M Maerevoet, C Herbaux… - 2018 - lilloa.univ-lille.fr
Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for
relapsed and refractory Hodgkin lymphoma: A series from Lysa centers. Toggle navigation …
relapsed and refractory Hodgkin lymphoma: A series from Lysa centers. Toggle navigation …
Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.
C Rossi, J Gilhodes, M Maerevoet… - American Journal of …, 2018 - europepmc.org
Anti-PD-1 therapy provides high response rates in Hodgkin lymphoma (HL) patients who
have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and …
have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and …
Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers
C Rossi, J Gilhodes, M Maerevoet… - American journal of … - pubmed.ncbi.nlm.nih.gov
Anti-PD-1 therapy provides high response rates in Hodgkin lymphoma (HL) patients who
have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and …
have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and …
[引用][C] Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa …
C Rossi, J Gilhodes, M Maerevoet… - American journal of …, 2018 - difusion.ulb.ac.be
Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers
C Rossi, J Gilhodes, M Maerevoet, C Herbaux… - American Journal of …, 2018 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Anti‐PD‐1 therapy provides high response
rates in Hodgkin lymphoma (HL) patients who have relapsed or are refractory (R/R) to …
rates in Hodgkin lymphoma (HL) patients who have relapsed or are refractory (R/R) to …